STANATE Trademark

Trademark Overview

On Wednesday, May 15, 2002, a trademark application was filed for STANATE with the United States Patent and Trademark Office. The USPTO has given the STANATE trademark a serial number of 76408361. The federal status of this trademark filing is REGISTERED AND RENEWED as of Saturday, June 28, 2014. This trademark is owned by Wellspring Pharmaceutical Corporation. The STANATE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for human use in the treatment of jaundice
stanate

General Information

Serial Number76408361
Word MarkSTANATE
Filing DateWednesday, May 15, 2002
Status800 - REGISTERED AND RENEWED
Status DateSaturday, June 28, 2014
Registration Number2851513
Registration DateTuesday, June 8, 2004
Mark Drawing1000 - Typeset: Word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, December 3, 2002

Trademark Statements

Goods and ServicesPharmaceuticals for human use in the treatment of jaundice

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, June 20, 2002
Primary Code005
First Use Anywhere DateFriday, February 25, 2000
First Use In Commerce DateMonday, February 2, 2004

Trademark Owner History

Party NameINFACARE PHARMACEUTICAL CORP.
Party Type31 - New Owner After Registration
Legal Entity Type03 - Corporation
AddressTrevose, PA 19053
Party NameWellspring Pharmaceutical Corporation
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressNeptune, NJ 07753
Party NameWellspring Pharmaceutical Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNeptune, NJ 07753
Party NameWellspring Pharmaceutical Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNeptune, NJ 07753

Trademark Events

Event DateEvent Description
Wednesday, November 22, 2023ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Thursday, June 8, 2023COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Wednesday, October 12, 2022ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Wednesday, July 13, 2022ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Wednesday, July 31, 2019ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Wednesday, November 1, 2017ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Saturday, June 28, 2014NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Saturday, June 28, 2014REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Saturday, June 28, 2014REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Saturday, June 28, 2014CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Monday, June 16, 2014TEAS SECTION 8 & 9 RECEIVED
Tuesday, June 10, 2014TEAS CHANGE OF CORRESPONDENCE RECEIVED
Saturday, June 19, 2010REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Saturday, June 19, 2010CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Wednesday, June 2, 2010TEAS SECTION 8 & 15 RECEIVED
Tuesday, June 8, 2004REGISTERED-PRINCIPAL REGISTER
Wednesday, March 31, 2004ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Friday, March 19, 2004ASSIGNED TO EXAMINER
Thursday, March 18, 2004CASE FILE IN TICRS
Tuesday, March 9, 2004STATEMENT OF USE PROCESSING COMPLETE
Tuesday, February 10, 2004USE AMENDMENT FILED
Tuesday, February 10, 2004PAPER RECEIVED
Wednesday, September 10, 2003SOU EXTENSION 1 GRANTED
Tuesday, August 19, 2003SOU EXTENSION 1 FILED
Tuesday, August 19, 2003PAPER RECEIVED
Tuesday, February 25, 2003NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 3, 2002PUBLISHED FOR OPPOSITION
Wednesday, November 13, 2002NOTICE OF PUBLICATION
Thursday, September 5, 2002APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 4, 2002ASSIGNED TO EXAMINER

Related Keywords

stanate jaundice treatment human pharmaceuticals